Patents by Inventor Delphine Borgel

Delphine Borgel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230265211
    Abstract: Vitamin K-dependent Protein S (PS) is a natural anticoagulant acting as a non-enzymatic cofactor for both activated protein C (APC) and tissue factor pathway inhibitor (TFPI). The inventors identify an anti-PS nanobody that very surprisingly enhances the APC-cofactor activity of PS through unknown mechanisms. Very interestingly, this nanobody exerts an antithrombotic effect in injured mesenteric microvessels of mice. As a consequence, it10 constitutes a novel class of antithrombotic agents that could be used for the treatment of acute microthrombosis in pathological states such as sepsis, COVID-19, distal microvascular thrombosis induced by stroke, or sickle-cell disease. Thus, the present invention relates to isolated single-domain antibodies (sdAb) directed against protein S (PS) and polypeptides comprising thereof.
    Type: Application
    Filed: June 28, 2021
    Publication date: August 24, 2023
    Inventors: François SALLER, Cécile DENIS, Delphine BORGEL, Frédéric BORGEL, Oliver CHRISTOPHE, Peter LENTING
  • Patent number: 8822654
    Abstract: The present invention relates to the use of a composition including of at least a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having no anticoagulant activity, for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: September 2, 2014
    Assignees: Universite Paris—Sud XI, Assistance Publique-Hopitaux de Paris, Universite Paris Descartes
    Inventors: Delphine Borgel, Véronique Ferger, Elsa Bianchini, Nicolas Lerolle, Jean-Luc René Diehl
  • Patent number: 8741844
    Abstract: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.
    Type: Grant
    Filed: July 18, 2008
    Date of Patent: June 3, 2014
    Assignee: Universite Paris-Sud XI
    Inventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini
  • Publication number: 20120088715
    Abstract: The present invention relates to the use of a composition including of at least a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having no anticoagulant activity, for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury.
    Type: Application
    Filed: January 15, 2010
    Publication date: April 12, 2012
    Applicants: UNIVERSITE PARIS-SUD XI, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini, Nicolas Lerolle, Rene Jean-Luc Diehl
  • Publication number: 20100298224
    Abstract: Use of a mutated antithrombin having substantially no activity, in particular no anticoagulant activity, possibly in association with an anticoagulant, for the preparation of a drug intended for the prevention or treatment of pathologies linked to or associated with coagulation disorders.
    Type: Application
    Filed: July 18, 2008
    Publication date: November 25, 2010
    Applicant: UNIVERSITE PARIS-SUD XI
    Inventors: Delphine Borgel born Botbol, Veronique Ferger born Picard, Elsa Bianchini